Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies

References

• Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–e47.22776238
   PubMed Web of Science ®Google Scholar
• Pratap R, Misra M, Morampudi S, Patil A, Reddy J. The existing scenario of haemophilia care in Canada and China - A review. Hematol Transfus Cell Ther. 2020;42(4):356–364. doi:10.1016/j.htct.2019.08.001
   Google Scholar
• Yang R, Poon MC, Luke KH, et al. Building a network for hemophilia care in China: 15 years of achievement for the hemophilia treatment center collaborative network of China. Blood Adv. 2019;3(Suppl 1):34–37. doi:10.1182/bloodadvances.2019GS12152431809551
   PubMed Web of Science ®Google Scholar
• Zhao H, Yang L, Long C, et al. Hemophilia care in China: review of care for 417 hemophilia patients from 11 treatment centers in Shanxi Province. Expert Rev Hematol. 2015;8(4):543–550. doi:10.1586/17474086.2015.104326325948487
   PubMed Web of Science ®Google Scholar
• O’Mahony B, Black C. Expanding hemophilia care in developing countries. Semin Thromb Hemost. 2005;31(5):561–568. doi:10.1055/s-2005-92222816276465
   PubMed Web of Science ®Google Scholar
• World Federation of Hemophilia. China joins Global Alliance for Progress; 2009 Available from: http://www.wfh.org/en/page.aspx?pid=808. Accessed: 87, 2019.
   Google Scholar
• Poon MC, Luke KH. Haemophilia care in China: achievements of a decade of World Federation of Hemophilia treatment centre twinning activities. Haemophilia. 2008;14(5):879–888. doi:10.1111/j.1365-2516.2008.01821.x18637966
   PubMed Web of Science ®Google Scholar
• Sun J, Zhao Y, Yang R, Guan T, Iorio A. On behalf of the Chinese Hero Study Group. The demographics, treatment characteristics and quality of life of adult people with haemophilia in China - results from the HERO study. Haemophilia. 2017;23(1):89–97. doi:10.1111/hae.1307127599642
   PubMed Web of Science ®Google Scholar
• Wu R, Luke KH. The benefit of low dose prophylaxis in the treatment of hemophilia: a focus on China. Expert Rev Hematol. 2017;10(11):995–1004. doi:10.1080/17474086.2017.138609628971697
   PubMed Web of Science ®Google Scholar
• Recht M, Nemes L, Matysiak M, et al. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII. Haemophilia. 2009;15(4):869–880.19473411
   PubMed Web of Science ®Google Scholar
• Windyga J, Rusen L, Gruppo R, et al. BDDrFVIII (moroctocog alfa [AF-CC]) for surgical haemostasis in patients with haemophilia A: results of a pivotal study. Haemophilia. 2010;16(5):731–739. doi:10.1111/j.1365-2516.2010.02239.x20412322
   PubMed Web of Science ®Google Scholar
• Kelley B, Jankowski M, Booth J. An improved manufacturing process for Xyntha/ReFacto AF. Haemophilia. 2010;16(5):717–725. doi:10.1111/j.1365-2516.2009.02160.x20041957
   PubMed Web of Science ®Google Scholar
• Yang R, Wu R, Sun J, et al. Safety and efficacy of moroctocog alfa (AF-CC) in patients with hemophilia A: Results of a post-authorization study in usual care settings in China [poster PB 230]. Presented at: Annual Congress of the International Society on Thrombosis and Haemostasis; 7 8–12; 2017; Berlin, Germany.
   Google Scholar
• Xyntha [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals (Pfizer Inc); 2015.
   Google Scholar
• Lusher JM, Lee CA, Kessler CM, Bedrosian CL. For the Refacto Phase 3 Study Group. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia. 2003;9(1):38–49. doi:10.1046/j.1365-2516.2003.00708.x
   PubMed Web of Science ®Google Scholar
• Lusher JM, Roth DA. The safety and efficacy of B-domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an update. Haemophilia. 2005;11(3):292–293. doi:10.1111/j.1365-2516.2005.01099.x15876278
   PubMed Web of Science ®Google Scholar
• Pollmann H, Externest D, Ganser A, et al. Efficacy, safety and tolerability of recombinant factor VIII (ReFacto) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria. Haemophilia. 2007;13(2):131–143. doi:10.1111/j.1365-2516.2006.01416.x17286765
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Picard JK, Schwaab R, Brackmann HH, Tuddenham EG, Simpson E. HLA genotype of patients with severe haemophilia A due to Intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost. 1997;77(2):238–242. doi:10.1055/s-0038-16559459157573
   PubMed Web of Science ®Google Scholar
• Wang XF, Zhao YQ, Yang RC, et al. The prevalence of factor VIII inhibitors and genetic aspects of inhibitor development in Chinese patients with haemophilia A. Haemophilia. 2010;16(4):632–639.20331753
   PubMed Web of Science ®Google Scholar
• DiMichele DM. Inhibitors in hemophilia: a primer, No. 7 In: Schulman S, editor. Treatment of Hemophilia. Montreal, Quebec, Canada: World Federation of Hemophilia; 2008:1–4.
   Google Scholar
• Walsh CE, Soucie JM, Miller CH. Impact of inhibitors on hemophilia A mortality in the United States. Am J Hematol. 2015;90(5):400–405. doi:10.1002/ajh.2395725616111
   PubMed Web of Science ®Google Scholar
• Gouw SC, van der Bom JG, Ljung R, et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013;368(3):231–239. doi:10.1056/NEJMoa120802423323899
   PubMed Web of Science ®Google Scholar
• Gouw SC, van den Berg HM, Fischer K, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood. 2013;121(20):4046–4055. doi:10.1182/blood-2012-09-45703623553768
   PubMed Web of Science ®Google Scholar
• Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood. 2007;109(11):4648–4654. doi:10.1182/blood-2006-11-05629117289808
   PubMed Web of Science ®Google Scholar
• Shi J, Zhao Y, Wu J, Sun J, Wang L, Yang R. Safety and efficacy of a sucrose-formulated recombinant factor VIII product for the treatment of previously treated patients with haemophilia A in China. Haemophilia. 2007;13(4):351–356. doi:10.1111/j.1365-2516.2007.01472.x17610547
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhao Y, Sun J, Wang X, Yu M, Yang R. Clinical observation on safety and efficacy of a plasma- and albumin-free recombinant factor VIII for on-demand treatment of Chinese patients with haemophilia A. Haemophilia. 2011;17(2):191–195. doi:10.1111/j.1365-2516.2010.02395.x20860578
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhao Y, Sun J, et al. Six-month clinical observation on safety and efficacy of a full-length recombinant factor VIII for on-demand treatment of Chinese patients with haemophilia A. Haemophilia. 2011;17(3):538–541. doi:10.1111/j.1365-2516.2010.02432.x21371179
   PubMed Web of Science ®Google Scholar
• Liu H, Wu R, Hu P, et al. An open-label, single-dose, pharmacokinetic study of factor VIII activity after administration of moroctocog alfa (AF-CC) in male Chinese patients with hemophilia A. Clin Ther. 2017;39(7):1313–1319. doi:10.1016/j.clinthera.2017.05.34428601434
   PubMed Web of Science ®Google Scholar
• Benjamin K, Vernon MK, Patrick DL, Perfetto E, Nestler-Parr S, Burke L. Patient-reported outcome and observer-reported outcome assessment in rare disease clinical trials: an ISPOR COA emerging good practices task force report. Value Health. 2017;20(7):838–855. doi:10.1016/j.jval.2017.05.01528712612
   PubMed Web of Science ®Google Scholar
• Spannheimer A The value of real-world evidence in rare disease research. CenterWatch presents news and views on the clinical trials industry; 2016 Available from: https://www.centerwatch.com/news-online/2016/03/08/value-real-world-evidence-rare-disease-research/. Accessed: 87, 2019.
   Google Scholar